EdgarLookup

LINCOLN ELECTRIC HOLDINGS INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that LINCOLN ELECTRIC HOLDINGS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
13.8%
Profit Margin
Net income ÷ revenue
13.8%
Return on Assets
Net income ÷ assets
1.57x
Debt-to-Equity
Total liabilities ÷ equity
+16.3%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2022 Dec 31, 2022 $3.76B Feb 21, 2023
FY2022 Dec 31, 2021 $3.23B Feb 21, 2023
FY2022 Dec 31, 2020 $2.66B Feb 21, 2023
FY2021 Dec 31, 2019 $3.00B Feb 18, 2022
FY2020 Dec 31, 2018 $3.03B Feb 19, 2021
FY2019 Dec 31, 2017 $2.62B Feb 27, 2020
FY2018 Dec 31, 2016 $2.27B Feb 27, 2019
FY2017 Dec 31, 2015 $2.54B Feb 27, 2018
FY2016 Dec 31, 2014 $2.81B Feb 24, 2017
FY2015 Dec 31, 2013 $2.85B Feb 25, 2016

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.23B Feb 25, 2026
FY2025 Dec 31, 2024 $4.01B Feb 25, 2026
FY2025 Dec 31, 2023 $4.19B Feb 25, 2026
FY2024 Dec 31, 2022 $3.76B Feb 26, 2025
FY2023 Dec 31, 2021 $3.23B Feb 27, 2024
FY2022 Dec 31, 2020 $2.66B Feb 21, 2023
FY2021 Dec 31, 2019 $3.00B Feb 18, 2022

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.53B Feb 25, 2026
FY2025 Dec 31, 2024 $1.47B Feb 25, 2026
FY2025 Dec 31, 2023 $1.47B Feb 25, 2026
FY2024 Dec 31, 2022 $1.28B Feb 26, 2025
FY2023 Dec 31, 2021 $1.07B Feb 27, 2024
FY2022 Dec 31, 2020 $871.34M Feb 21, 2023
FY2019 Dec 31, 2019 $240.93M Feb 27, 2020
FY2019 Sep 30, 2019 $238.35M Feb 27, 2020
FY2019 Jun 30, 2019 $269.88M Feb 27, 2020
FY2019 Mar 31, 2019 $258.42M Feb 27, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $520.53M Feb 25, 2026
FY2025 Dec 31, 2024 $466.11M Feb 25, 2026
FY2025 Dec 31, 2023 $545.25M Feb 25, 2026
FY2024 Dec 31, 2022 $472.22M Feb 26, 2025
FY2023 Dec 31, 2021 $276.58M Feb 27, 2024
FY2022 Dec 31, 2020 $206.12M Feb 21, 2023
FY2021 Dec 31, 2019 $293.11M Feb 18, 2022
FY2020 Dec 31, 2018 $287.07M Feb 19, 2021
FY2010 Dec 31, 2010 $130.24M Feb 28, 2011
FY2010 Dec 31, 2009 $48.58M Feb 28, 2011

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $718.06M Feb 25, 2026
FY2025 Dec 31, 2024 $636.46M Feb 25, 2026
FY2025 Dec 31, 2023 $717.85M Feb 25, 2026
FY2024 Dec 31, 2022 $612.34M Feb 26, 2025
FY2023 Dec 31, 2021 $461.67M Feb 27, 2024
FY2022 Dec 31, 2020 $282.07M Feb 21, 2023
FY2021 Dec 31, 2019 $370.91M Feb 18, 2022
FY2020 Dec 31, 2018 $375.54M Feb 19, 2021
FY2019 Dec 31, 2017 $376.94M Feb 27, 2020
FY2018 Dec 31, 2016 $283.61M Feb 27, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $85.55M Feb 25, 2026
FY2025 Dec 31, 2024 $81.82M Feb 25, 2026
FY2025 Dec 31, 2023 $71.24M Feb 25, 2026
FY2024 Dec 31, 2022 $63.21M Feb 26, 2025
FY2023 Dec 31, 2021 $55.97M Feb 27, 2024
FY2022 Dec 31, 2020 $51.41M Feb 21, 2023
FY2021 Dec 31, 2019 $56.85M Feb 18, 2022
FY2020 Dec 31, 2018 $54.17M Feb 19, 2021
FY2019 Dec 31, 2017 $47.90M Feb 27, 2020
FY2018 Dec 31, 2016 $44.72M Feb 27, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $797.99M Feb 25, 2026
FY2025 Dec 31, 2024 $780.59M Feb 25, 2026
FY2025 Dec 31, 2023 $758.91M Feb 25, 2026
FY2024 Dec 31, 2022 $656.64M Feb 26, 2025
FY2023 Dec 31, 2021 $597.11M Feb 27, 2024
FY2022 Dec 31, 2020 $543.80M Feb 21, 2023
FY2021 Dec 31, 2019 $621.49M Feb 18, 2022
FY2020 Dec 31, 2018 $627.70M Feb 19, 2021
FY2019 Dec 31, 2017 $541.23M Feb 27, 2020
FY2018 Dec 31, 2016 $468.60M Feb 27, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $661.17M Feb 25, 2026
FY2025 Dec 31, 2024 $598.98M Feb 25, 2026
FY2025 Dec 31, 2023 $667.54M Feb 25, 2026
FY2024 Dec 31, 2022 $383.39M Feb 26, 2025
FY2023 Dec 31, 2021 $365.06M Feb 27, 2024
FY2022 Dec 31, 2020 $351.36M Feb 21, 2023
FY2021 Dec 31, 2019 $403.19M Feb 18, 2022
FY2020 Dec 31, 2018 $329.15M Feb 19, 2021
FY2019 Dec 31, 2017 $334.85M Feb 27, 2020
FY2010 Dec 31, 2010 $156.98M Feb 28, 2011

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.78B Feb 25, 2026
FY2025 Dec 31, 2024 $3.52B Feb 25, 2026
FY2024 Dec 31, 2023 $3.38B Feb 26, 2025
FY2024 Dec 31, 2022 $3.18B Feb 26, 2025
FY2023 Dec 31, 2021 $2.59B Feb 27, 2024
FY2022 Dec 31, 2020 $2.31B Feb 21, 2023
FY2021 Dec 31, 2019 $2.37B Feb 18, 2022
FY2020 Dec 31, 2018 $2.35B Feb 19, 2021
FY2019 Dec 31, 2017 $2.41B Feb 27, 2020
FY2018 Dec 31, 2016 $1.94B Feb 27, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.31B Feb 25, 2026
FY2025 Dec 31, 2024 $2.19B Feb 25, 2026
FY2024 Dec 31, 2023 $2.07B Feb 26, 2025
FY2023 Dec 31, 2022 $2.15B Feb 27, 2024
FY2022 Dec 31, 2021 $1.73B Feb 21, 2023
FY2021 Dec 31, 2020 $1.52B Feb 18, 2022
FY2020 Dec 31, 2019 $1.55B Feb 19, 2021
FY2019 Dec 31, 2018 $1.46B Feb 27, 2020
FY2018 Dec 31, 2017 $1.47B Feb 27, 2019
FY2017 Dec 31, 2016 $1.23B Feb 27, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.47B Feb 25, 2026
FY2025 Dec 31, 2024 $1.33B Feb 25, 2026
FY2025 Dec 31, 2023 $1.31B Feb 25, 2026
FY2025 Dec 31, 2022 $1.03B Feb 25, 2026
FY2024 Dec 31, 2021 $863.91M Feb 26, 2025
FY2023 Dec 31, 2020 $790.25M Feb 27, 2024
FY2020 Dec 31, 2019 $818.17M Feb 19, 2021
FY2019 Dec 31, 2018 $886.94M Feb 27, 2020
FY2018 Dec 31, 2017 $931.64M Feb 27, 2019
FY2017 Dec 31, 2016 $711.48M Feb 27, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $886.69M Feb 25, 2026
FY2025 Dec 31, 2024 $804.93M Feb 25, 2026
FY2025 Dec 31, 2023 $694.45M Feb 25, 2026
FY2024 Dec 31, 2022 $665.26M Feb 26, 2025
FY2023 Dec 31, 2021 $430.16M Feb 27, 2024
FY2022 Dec 31, 2020 $335.59M Feb 21, 2023
FY2021 Dec 31, 2019 $337.11M Feb 18, 2022
FY2020 Dec 31, 2018 $281.29M Feb 19, 2021
FY2019 Dec 31, 2017 $234.58M Feb 27, 2020
FY2018 Dec 31, 2016 $231.92M Feb 27, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.34B Feb 25, 2026
FY2025 Dec 31, 2024 $3.99B Feb 25, 2026
FY2024 Dec 31, 2023 $3.69B Feb 26, 2025
FY2023 Dec 31, 2022 $3.31B Feb 27, 2024
FY2022 Dec 31, 2021 $2.97B Feb 21, 2023
FY2021 Dec 31, 2020 $2.82B Feb 18, 2022
FY2020 Dec 31, 2019 $2.74B Feb 19, 2021
FY2019 Dec 31, 2018 $2.56B Feb 27, 2020
FY2018 Dec 31, 2017 $2.39B Feb 27, 2019
FY2017 Dec 31, 2016 $2.24B Feb 27, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $308.79M Feb 25, 2026
FY2025 Dec 31, 2024 $377.26M Feb 25, 2026
FY2024 Dec 31, 2023 $393.79M Feb 26, 2025
FY2023 Dec 31, 2022 $197.15M Feb 27, 2024
FY2022 Dec 31, 2021 $192.96M Feb 21, 2023
FY2021 Dec 31, 2020 $257.28M Feb 18, 2022
FY2020 Dec 31, 2019 $199.56M Feb 19, 2021
FY2019 Dec 31, 2018 $358.85M Feb 27, 2020
FY2018 Dec 31, 2017 $326.70M Feb 27, 2019
FY2017 Dec 31, 2016 $379.18M Feb 27, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2023 Dec 31, 2023 $1.10B Feb 27, 2024
FY2023 Dec 31, 2022 $1.12B Feb 27, 2024
FY2022 Dec 31, 2021 $717.86M Feb 21, 2023
FY2021 Dec 31, 2020 $715.57M Feb 18, 2022
FY2020 Dec 31, 2019 $712.41M Feb 19, 2021

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 9 Feb 25, 2026
FY2025 Dec 31, 2024 8 Feb 25, 2026
FY2025 Dec 31, 2023 9 Feb 25, 2026
FY2024 Dec 31, 2022 8 Feb 26, 2025
FY2023 Dec 31, 2021 4 Feb 27, 2024
FY2022 Dec 31, 2020 3 Feb 21, 2023
FY2019 Dec 31, 2019 1 Feb 27, 2020
FY2019 Sep 30, 2019 1 Feb 27, 2020
FY2019 Jun 30, 2019 1 Feb 27, 2020
FY2019 Mar 31, 2019 1 Feb 27, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 9 Feb 25, 2026
FY2025 Dec 31, 2024 8 Feb 25, 2026
FY2025 Dec 31, 2023 9 Feb 25, 2026
FY2024 Dec 31, 2022 8 Feb 26, 2025
FY2023 Dec 31, 2021 4 Feb 27, 2024
FY2022 Dec 31, 2020 3 Feb 21, 2023
FY2019 Dec 31, 2019 1 Feb 27, 2020
FY2019 Sep 30, 2019 1 Feb 27, 2020
FY2019 Jun 30, 2019 1 Feb 27, 2020
FY2019 Mar 31, 2019 1 Feb 27, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 54.85M Feb 25, 2026
FY2025 Dec 31, 2024 56.21M Feb 25, 2026
FY2024 Dec 31, 2023 56.98M Feb 26, 2025
FY2023 Dec 31, 2022 57.62M Feb 27, 2024
FY2022 Dec 31, 2021 58.79M Feb 21, 2023
FY2021 Dec 31, 2020 59.64M Feb 18, 2022
FY2020 Dec 31, 2019 60.59M Feb 19, 2021
FY2019 Dec 31, 2018 63.55M Feb 27, 2020
FY2018 Dec 31, 2017 65.66M Feb 27, 2019
FY2017 Dec 31, 2016 65.67M Feb 27, 2018

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $168.24M Feb 25, 2026
FY2025 Dec 31, 2024 $162.14M Feb 25, 2026
FY2025 Dec 31, 2023 $148.01M Feb 25, 2026
FY2024 Dec 31, 2022 $130.72M Feb 26, 2025
FY2023 Dec 31, 2021 $121.85M Feb 27, 2024
FY2022 Dec 31, 2020 $118.12M Feb 21, 2023
FY2021 Dec 31, 2019 $117.92M Feb 18, 2022
FY2020 Dec 31, 2018 $102.06M Feb 19, 2021
FY2019 Dec 31, 2017 $92.45M Feb 27, 2020
FY2018 Dec 31, 2016 $87.33M Feb 27, 2019